Skip to main content
. 2017 Jan 6;8(7):10931–10944. doi: 10.18632/oncotarget.14539

Table 1. Proliferation IC50 (nM) of FLT3 TKI against AL mutants.

FLT3
mutants
mut
Midostaurin Lestaurtinib AG1295 AGS324 Linifanib Quizartinib Sunitinib Sorafenib TTT-3002 R406 KW2449 Crenolanib Ponatinib
FLT3-ITD 9.3 8.6 297.9 65.3 2.4 1.2 5.4 18.5 <1.0 165.6 41.0 57.0 <1.0
D835Y 10.0 9.8 >3000 >3000 >100 >100 >100 >2000 4.1 >200 >200 58.0 92.0
D835A 5.0 5.0 1972.0 >200 >200 >200 >200 >200.0 1.3 >200 62.0 78.1 148.2
D835G 7.9 6.0 423.0 60.1 8.6 9.0 48.1 34.5 <1.0 141.0 56.0 110 <1.0
D835N 8.4 7.6 411.1 100 10.3 7.2 46.4 31.6 <1.0 153.0 58.3 80.0 <1.0
D835L+K 1.0 2.1 >3000 >3000 >200 >200 >200 >200 6.7 >200 >200 >1000 >1000
I836L+D 5.2 2.1 >3000 >3000 >200 >200 >200 >200 11.7 >200 >200 50.0 <1.0
I836S 10.2 15.0 >3000 >200 >200 >200 >200 10.2 9.0 >200 >200 >1000 >1000
I836T 10.0 13.4 >3000 >3000 5.3 6.8 6.0 48.2 9.7 152.0 31.9 >1000 >1000
840G+S 12.0 8.0 500.0 50.0 2.1 2.5 4.0 5.0 <1.0 >200 35.0 83.0 <1.0
D593D 2.4 8.0 >3000 >200 >200 >200 >200 >200.0 2.8 >200 >200 70.0 10.7